Werewolf Therapeutics (NASDAQ:HOWL – Get Free Report)‘s stock had its “outperform” rating restated by research analysts at Wedbush in a report issued on Monday, RTT News reports. They presently have a $9.00 price objective on the stock. Wedbush’s target price indicates a potential upside of 50.50% from the stock’s current price. A number of other […]